ABSTRACT
OBJECTIVES: The object of this study was to introduce the KORean Observational study Network for Arthritis (KORONA) registry with an emphasis on the design of the Korean rheumatoid arthritis (RA) national database, as well as to provide an overview of the RA patients who are currently registered in KORONA. METHODS: The KORONA was established in July 2009 by the Clinical Research Center for Rheumatoid Arthritis (CRCRA) in South Korea. KORONA is based on a prospective protocol and standard, defined data collection instruments. Demographic and clinical features, laboratory and radiologic data, health-related outcomes, treatment side effects, resource utilization, and health behaviors of the RA cohort patients are recorded in a database. RESULTS: A total of 23 institutions, which are about 38% of the rheumatologic departments at tertiary academic hospitals across South Korea, are part of KORONA. The quality control of data collection and management has been performed through annual monitoring and auditing, staff training, and providing standard operation protocol by the executive committee of CRCRA. As of 31 December 2010, 4721 patients with established RA were included in KORONA, because an annual survey had started to be performed in July 2010. CONCLUSIONS: KORONA is the first nationwide Korean RA-specific cohort and it will provide valuable "real-world" information for Korean RA patients.
Subject(s)
Arthritis, Rheumatoid/diagnosis , Databases, Factual , Registries , Research Design , Adult , Aged , Aged, 80 and over , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Cohort Studies , Female , Humans , Male , Middle Aged , Prospective Studies , Republic of KoreaSubject(s)
Carcinoma/diagnosis , Coccidioides/isolation & purification , Coccidioidomycosis/diagnosis , Lung Diseases, Fungal/diagnosis , Lung Neoplasms/diagnosis , Peritoneal Diseases/diagnosis , Peritoneal Neoplasms/diagnosis , Antifungal Agents/therapeutic use , Biopsy , Coccidioidomycosis/drug therapy , Coccidioidomycosis/microbiology , Diagnosis, Differential , Endoscopy, Gastrointestinal , Female , Humans , Lung Diseases, Fungal/complications , Lung Diseases, Fungal/drug therapy , Middle Aged , Peritoneal Diseases/complications , Peritoneal Diseases/drug therapy , Positron-Emission Tomography , Tomography, X-Ray ComputedABSTRACT
Widdrol, an odorous compound extracted from Juniperus chinensis, has been shown to inhibit the in vitro growth of in human cancer cells. This study was conducted on cultured human colon adenocarcinoma HT29 cells to elucidate the possible mechanisms by which widdrol exerts its anti-proliferative activity, which until now has remained poorly understood. It was found that widdrol induces accumulation of sub-G1 phase and arrests in the G1 phase of the cell cycle. Induction of G1 arrest by widdrol was correlated with induction of Chk2, p53 phosphorylation and CDK inhibitor p21 expression as well as inhibition of cyclin E, cyclin-dependent kinase (CDK2) and retinoblastoma protein (pRB). Moreover, mini-chromosome maintenance (MCM) proteins were markedly down-regulated in HT29 cells treated with widdrol. Altogether, these results show widdrol possesses potential anti-cancer activity against colon adenocarcinoma cells by inhibiting their proliferation and inducing cell cycle G1 arrest.
Subject(s)
Adenocarcinoma/metabolism , Benzocycloheptenes/pharmacology , Cell Cycle Proteins/drug effects , Colonic Neoplasms/metabolism , Plant Extracts/pharmacology , Blotting, Western , Cell Cycle/drug effects , Cell Cycle Proteins/metabolism , Cell Separation , Down-Regulation , Flow Cytometry , Gene Expression/drug effects , Gene Expression Profiling , HT29 Cells , Humans , Immunoprecipitation , Juniperus/chemistry , Minichromosome Maintenance 1 Protein/drug effects , Minichromosome Maintenance 1 Protein/metabolism , Minichromosome Maintenance Complex Component 2 , Nuclear Proteins/drug effects , Nuclear Proteins/metabolism , Oligonucleotide Array Sequence Analysis , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
We report a rare case of patient with dermatomyositis (DM) who developed spontaneous pneumomediastinum (PnM) and subcutaneous emphysema. She was successfully treated with oral prednisolone and cyclosporine A (CsA). We reviewed the cases of PnM in patients with DM treated with CsA. A review of four previously reported cases revealed that treatment with systemic glucocorticoid and CsA was effective for the DM and PnM. We indicate that initial and early treatment of the patients with DM and PnM with CsA enabled rapid tapering of the dose of glucocorticoid and improved the disease.
Subject(s)
Cyclosporine/therapeutic use , Dermatomyositis/complications , Dermatomyositis/drug therapy , Immunosuppressive Agents/therapeutic use , Mediastinal Emphysema/drug therapy , Mediastinal Emphysema/etiology , Adult , Dermatomyositis/diagnostic imaging , Female , Follow-Up Studies , Humans , Mediastinal Emphysema/diagnostic imaging , Time Factors , Tomography, X-Ray Computed/adverse effects , Treatment OutcomeABSTRACT
Intractable fever in cancer patients is problematic and the causes of this fever can be diverse. Paroxysmal persistent hyperthermia after sudden mental change or neurologic deficit can develop via autonomic dysregulation without infection or any other causes of fever. Paroxysmal hyperthermic autonomic dysregulation is a rare disease entity. It manifests as a form of paroxysmal hypertension, fever, tachycardia, tachypnea, pupillary dilation, agitation and extensor posturing after traumatic brain injury, hydrocephalus, brain hemorrhage or brain neoplasm. We recently experienced a case of paroxysmal hyperthermia following intracerebral hemorrhage along with brain neoplasm. Extensive fever workups failed to show an infectious or inflammatory source and/or hormonal abnormality. Empirical treatments with antibiotics, antipyretics, morphine, steroid and antiepileptic agents were also ineffective. However, Propranolol, a lipophilic beta-blocker, successfully controlled the fever and stabilized the patient. Fever in cancer patients is a common phenomenon, but a central origin should be considered when the fever is intractable. Propranolol is one of the most effective drugs for treating paroxysmal hyperthermia that is due to autonomic dysregulation.
